

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

**Item 1: Name and Address of Reporting Issuer**

PUF Ventures Inc. (the “Company”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

**Item 2: Date of Material Change**

February 20, 2018.

**Item 3: News Release**

A news release was issued and disseminated on February 20, 2018 and filed on SEDAR ([www.sedar.com](http://www.sedar.com)).

**Item 4: Summary of Material Changes**

The Company and its strategic partner MYM Nutraceuticals (CSE: MYM) announce a joint venture agreement between Southern Cross University and Solaris Nutraceuticals.

**Item 5: Full Description of Material Change**

The Company and its strategic partner MYM Nutraceuticals (CSE: MYM) announce a joint venture agreement between Southern Cross University and Solaris Nutraceuticals to commit to the development of hemp and medicinal cannabis products in the NSW Northern Rivers region that will enhance animal and human health. The agreement will pave the way for a flourishing industry built on the medicinal value of cannabis.

Vice-Chancellor Professor Adam Shoemaker said the agreement was a great step forward not just for the region, but also for consumers.

Professor Shoemaker signed the agreement with Mr. Michael Horsfall, CEO of Solaris Nutraceuticals, committing to a new approach that brings together the University’s internationally-recognized expertise in medicinal cannabis research with the corporate capabilities of Solaris Nutraceuticals.

The University’s Lismore campus is equipped with high-security research laboratories where researchers work with the world’s most diverse collection of cannabis seed and has already established an international reputation for botanical research. The decision of Solaris to establish a new medicinal cannabis plant in Casino, just a half hour drive from Lismore, has underscored the potential of this collaboration to yield substantial outcomes.

**About Southern Cross University**

Australia’s engaged university, Southern Cross, has maximized its impact by forging close partnerships with industry, communities and research partners around the world. With campuses in Lismore, Coffs Harbour and the Gold Coast, Southern Cross was founded in 1994 and is already ranked by Times Higher Education (THE) in the top 500 universities in the world, including ranking in the top 300 for life sciences.

**About Solaris Nutraceuticals Inc.**

Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney, Australia. The Company is owned by PUF Ventures Inc. (CSE: PUF), MYM Nutraceuticals Inc. (CSE: MYM), Chrome Holdings of Australia and private investors. It has submitted applications and plans with Australia's Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales, Australia. Solaris' corporate mission is to deliver environmentally friendly, sun grown medicinal grade cannabis and to develop medicines and treatments for pain management and other medical conditions. The company's focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients. For more information, visit [www.solarisnutraceuticals.com](http://www.solarisnutraceuticals.com).

**About PUF Ventures Inc.**

PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. The Company has an option to purchase 100% of AAA Heidelberg Inc., a private Ontario company and advanced applicant for an ACMPR license. Solaris Nutraceuticals is building the largest medical cannabis greenhouse in the Southern Hemisphere. For more information please visit: [www.puf.ca](http://www.puf.ca).

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the release.

Some of the statements contained in the release are forward-looking statements, such as estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

**Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7: Omitted Information**

None.

**Item 8: Executive Officer**

For further information, please contact:

Tim McNulty  
T: 1 (800) 783.6056 Ext. 3  
E: [ir@puf.ca](mailto:ir@puf.ca)

**Item 9: Date of Report**

February 20, 2018.